Resverlogix, Medtronic sign DES (drug-eluting stent) licensing pact
This article was originally published in Clinica
Executive Summary
In a bid to expand its drug-eluting stent (DES) portfolio, Medtronic has entered a licensing deal with Canadian biotech company Resverlogix whereby the medtech giant will gain exclusive, worldwide access to the latter's ReVas cardiovascular drug programme. The agreement will see Calgary, Alberta-based Resverlogix receive up to Can$340m (US$291m) in milestone payments and royalties from its new partner.